End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
19.3 CNY | -1.48% | +2.50% | -16.34% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.34% | 4.53B | C+ | ||
+40.09% | 6.3B | B- | ||
-7.11% | 3.29B | B- | ||
+5.14% | 3.2B | C | ||
-0.18% | 2.63B | - | D+ | |
+47.93% | 1.97B | - | ||
-7.15% | 1.74B | - | - | |
+0.67% | 1.69B | - | - | |
-8.73% | 1.64B | C- | ||
+48.97% | 1.52B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002603 Stock
- Ratings Shijiazhuang Yiling Pharmaceutical Co., Ltd.